scholarly journals Effect of short-term, high-dose methylprednisolone on oxidative stress in children with acute immune thrombocytopenia

2016 ◽  
Vol 51 (4) ◽  
pp. 261
Author(s):  
Musa Cura ◽  
Ahmet Koç ◽  
Nurten Aksoy ◽  
Zeynep Canan Özdemir
2019 ◽  
Vol 2019 (11) ◽  
pp. 486-489 ◽  
Author(s):  
Nata Pratama Hardjo Lugito ◽  
Jane Olivia Lorens ◽  
Jessica Kwenandar ◽  
Andree Kurniawan

Abstract The multifactorial mechanisms of immune thrombocytopenia (ITP) in patients with human immunodeficiency virus (HIV) and tuberculosis (TB) could be caused by HIV, TB or anti-TB drugs. No patients with HIV and opportunistic infection of miliary pulmonary TB who developed thrombocytopenia after treatment with anti-TB drugs have been reported. A 47-year-old woman with HIV/acquired immunodeficiency syndrome and miliary TB with normal platelet count (229 000/μL) started anti-TB drugs (rifampicin, isoniazid, pyrazinamide and ethambutol). After 10 days of treatment, her platelet count was low (17 000/μL). As rifampicin and isoniazid were stopped and intravenous methylprednisolone was given, her platelet count began to increase. After more than a month, her platelet count was normal (192 000/μL) and she started antiretrovirals. This improved platelet count after high-dose methylprednisolone is suggestive of ITP; however, the dilemma is whether it was rifampicin alone that caused ITP or did HIV and disseminated TB infection also play a role?


2015 ◽  
Vol 14 (2) ◽  
pp. 211-218 ◽  
Author(s):  
Marianne Skov ◽  
Tacjana Pressler ◽  
Jens Lykkesfeldt ◽  
Henrik Enghusen Poulsen ◽  
Peter Østrup Jensen ◽  
...  

2015 ◽  
Vol 40 (4) ◽  
Author(s):  
Cuma Mertoğlu ◽  
Zeynep Küskü Kiraz ◽  
Erkan Söğüt ◽  
Hüseyin Özyurt

AbstractObjective: Glucocorticoids have been used in the treatment of a number of diseases due to their widely therapeutic effects. But they have serious side effects. Although glucocorticoid therapy is an effective measure to prevent and treat many diseases in patients, it can cause adverse effects on the cardiovascular system secondary to oxidative stress. It has been suggested that melatonin is a potent antioxidant and that melatonin supplements may protect against such age-related diseases as atherosclerosis, cancer, and Alzheimer disease. In this study, we investigated whether such effects of a single high dose steroid has adverse consequences for the oxidant-antioxidant system of rabbit heart tissue and whether melatonin treatment is protective in the rabbit. For this purpose we measurument some biochemical parameters in the rabbit heart tissue.Methods: Level of malondialdehyde (MDA, a lipid peroxidation product), protein carbonyl (PC, a protein oxidation product) and nitric oxide (NO) were measured from heart tissue samples of all rabbits included in the study. Also antioxidant enzymes superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase activities were measured from heart tissues. In the study, 20 rabbits were used. The rabbits were separated into three groups. Group I: Control group, group II: Methylprednisolone group, group III: Methylprednisolone plus melatonin group.Results: The results of the study; PC levels significantly decreased in methylprednisolone plus melatoninin group compared to the control group (p=0.03). PC levels decreased in methlyprednisolone group compared to the control group and higher than methlyprednisolone + melatonin group but these changes aren’t significant statistically. No statistical difference was determined by MDA, NO levels and SOD, GSH-Px, catalase activities of all groups.Conclusion: According to the results of this study we can say that administration of a single high dose methylprednisolone doesn’t increase oxidative stress Also, melatonine is a potent antioxidant agent in the heart tissue.


Author(s):  
Stephanie E. Reuter ◽  
Hayley B. Schultz ◽  
Michael B. Ward ◽  
Crystal L. Grant ◽  
Gemma M. Paech ◽  
...  

2020 ◽  
pp. 1-6
Author(s):  
Masuho Saburi ◽  
Masao Ogata ◽  
Yasuhiro Soga ◽  
Takako Satou ◽  
Kazuhito Itani ◽  
...  

<b><i>Objective:</i></b> Platelet-associated immunoglobulin G (PA-IgG) refers to IgG attached to the surface of platelets, while the immature platelet fraction (IPF) reflects the state of platelet production in bone marrow. Since PA-IgG and IPF are increased in patients with immune thrombocytopenia (ITP), reflecting amounts of platelet antibodies and compensatory platelet production, respectively, we hypothesized that these laboratory findings may provide useful markers for predicting treatment response in patients with ITP. We therefore retrospectively investigated associations between levels of these markers at diagnosis and response to first-line therapy in patients with ITP. <b><i>Methods:</i></b> Forty-three patients diagnosed with ITP at Oita Kouseiren Tsurumi Hospital between May 2010 and November 2018 were included. Patients were divided into 2 groups based on response to corticosteroid as first-line therapy. Laboratory findings were compared between responders and nonresponders. <b><i>Results:</i></b> Median PA-IgG was 285 ng/10<sup>7</sup> cells (range, 45.5–18,200 ng/10<sup>7</sup> cells), and median IPF was 15.5% (range, 5.4–62.1%). Median levels were higher than the respective upper limits of normal range (PA-IgG, 0–46 ng/10<sup>7</sup> cells; IPF, 1.1–9.5%). First-line therapy was performed using standard-dose prednisolone (0.5–1.0 mg/kg/day) in 32 patients and high-dose dexamethasone (40 mg/day, 4 days) or methylprednisolone (125–1,000 mg/day, 3–4 days) in 11 patients. Twenty-four patients (55.8%) responded to first-line therapy. In univariate analysis, type of corticosteroid (<i>p</i> = 0.17) tended to differ between groups but did not differ significantly, and no difference in IPF level was apparent between responders (15.35%; range, 5.4–41.5%) and nonresponders (16.7%; range, 6.3–62.1%; <i>p</i> = 0.15). PA-IgG was significantly higher among nonresponders (430 ng/10<sup>7</sup> cells; range, 101–18,200 ng/10<sup>7</sup> cells) than among responders (254.5 ng/10<sup>7</sup> cells; range, 45.5–470 ng/10<sup>7</sup> cells; <i>p</i> = 0.004). Multivariate analysis revealed PA-IgG was independently associated with response to first-line therapy (odds ratio, 1.000; 95% confidence interval, 1.000–1.010; <i>p</i> = 0.029). <b><i>Conclusion:</i></b> Our data suggested that PA-IgG at diagnosis could offer a useful predictor of response to first-line corticosteroid therapy for ITP.


Sign in / Sign up

Export Citation Format

Share Document